Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression change in Skov3 after EZH2 knockdown

ABSTRACT: To identify genes whose expression was suppressed by EZH2, we performed gene expression microarray analysis in control and EZH2 knockdown human SKOV3 EOC cells. Two individual short hairpin RNAs to the human EZH2 gene (shEZH2) were used to limit potential off-target effects.

ORGANISM(S): Homo sapiens

PROVIDER: GSE31433 | GEO | 2011/12/12

SECONDARY ACCESSION(S): PRJNA145795

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Gene expression change in Skov3 after EZH2 knockdown

Project description:To identify genes whose expression was suppressed by EZH2, we performed gene expression microarray analysis in control and EZH2 knockdown human SKOV3 EOC cells. Two individual short hairpin RNAs to the human EZH2 gene (shEZH2) were used to limit potential off-target effects. Two individual short hairpin RNAs to the human EZH2 gene (shEZH2) were used to limit potential off-target effects. Three technical replicates per group were used.

2011-12-12 | E-GEOD-31433 | biostudies-arrayexpress

EZH2 and H3K27ac ChIPseq of SKOV3(AA) and SKOV3(CC)

Project description:EZH2 and H3K27ac ChIPseq of SKOV3(AA) and SKOV3(CC)

| PRJNA771867 | ENA

Expression data from SKOV3 KO1#_Vector and SKOV3 KO1#_MED12 rescued cells

Project description:Epithelial ovarian cancer (EOC) is the leading cause of death among all gynecological malignancies due to high rate of disease relapse. Disease relapse in cancer patients after clinical remission are often referred to tumor dormancy. Here we identify the RNA polymerase II transcriptional Mediator subunit 12 (MED12) as an important molecular regulator of tumor dormancy. We found that MED12 knock-out (KO) could induce dormancy of EOC cells in vitro and in vivo. Mechanistically, microarray analysis showed that MED12 KO decreased the expression of EGFR. Hierarchical cluster assays of the differentially expressed genes between SKOV3 KO1#_Vector and SKOV3 KO1#_MED12 cells

2018-04-10 | GSE112887 | GEO

knockout of EZH2 inhibits the tumorigenicity of human ovarian cancers cells SKOV3 by targeting steroid biosynthesis

Project description:Ovarian cancer has the highest mortality in gynecologic cancers and most patients are diagnosed in advanced stages. EZH2 has been a major tumor markers and effective therapeutic targets for ovarian cancer, which molecular mechanism remain unclear. The present study was investigated the biological effects on EZH2 knock-out SKOV3 cells in vitro and in vivo experiment, and explore the molecular mechanism by integrated analysis of mRNA-seq and CHIP-seq.  CRISPR/Cas9 system was used to establish the knock-out EZH2 SKOV3 cells. Protein expression was detected by Western blot. The effect of EZH2 in ovarian cancer was detected by MTT assay, wound scratch assay and Transwell assay, apoptosis assay in vitro and xenograft model in vivo. mRNA-seq and CHIP-seq was used to explore the molecular mechanism of biological function of EZH2.

2020-02-22 | GSE145692 | GEO

The effect of EZH2 knockdown on gene expression in KDM6A-deficient KYSE180 cells following exposure to ionizing radiation [RNA-seq]

Project description:To elucidate the mechanism by which EZH2 regulates the radiosensitivity of KDM6A-deficient ESCC cells, we established KYSE180-shEZH2 and control KYSE180-shluc cells. 48 hours after exposure to 6Gy IR, we performed gene expression profiling analysis using RNA-seq data from KYSE180-shEZH2 and control KYSE180-shluc.

2024-04-22 | GSE264079 | GEO

Gene expression profiling of two DLBCL cell lines upon shRNA mediated knockdown of EZH2

Project description:We studied transcriptional changes by Affymetrix human microarrays in 2 DLBCL cell lines as a result of shRNA mediated knockdown of EZH2. In eukaryotes, epigenetic post-translational modification of histones is critical for regulation of chromatin structure and gene expression. EZH2 is the catalytic subunit of the Polycomb Repressive Complex 2 (PRC2) and is responsible for repressing target gene expression through methylation of histone H3 on lysine 27 (H3K27). Over-expression of EZH2 is implicated in tumorigenesis and correlates with poor prognosis in multiple tumor types. Recent reports have identified somatic heterozygous mutations of Y641 and A677 residues within the catalytic SET domain of EZH2 in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). The Y641 residue is the most frequently mutated residue, with 22% of GCB (Germinal Cell B-cell) DLBCL and FL harboring mutations at this site. These lymphomas exhibit increased H3K27 tri-methylation (H3K27me3) due to altered substrate preferences of the mutant enzymes. However, it is unknown whether direct inhibition of EZH2 methyltransferase activity alone will be effective in treating lymphomas carrying activating EZH2 mutations. Herein, we demonstrate that GSK126, a potent, highly-selective, SAM-competitive, small molecule inhibitor of EZH2 methyltransferase activity, decreases global H3K27me3 levels and reactivates silenced PRC2 target genes. GSK126 effectively inhibits the proliferation of EZH2 mutant DLBCL cell lines and dramatically inhibits the growth of EZH2 mutant DLBCL xenografts in mice. Together, these data demonstrate that pharmacological inhibition of EZH2 activity may provide a promising treatment for EZH2 mutant lymphoma. Pfeiffer and KARPAS-422 cells were treated with either shRNA targeting EZH2 (shEZH2) or a non targeting control (shNTC) for 10 days.

2012-10-12 | E-GEOD-41239 | biostudies-arrayexpress

Expression data from WT and MED12 KO SKOV3 and HO8910 cells

2018-04-10 | GSE112888 | GEO

EZH2 promotes a bi-lineage identity in basal-like breast cancer cells

Project description:The mechanisms regulating breast cancer differentiation state are poorly understood. Of particular interest are molecular regulators controlling the highly aggressive and poorly differentiated traits of basal-like breast carcinomas. Here we show that the Polycomb factor EZH2 maintains the differentiation state of basal-like breast cancer cells, and promotes the expression of progenitor-associated and basal-lineage genes. Specifically, EZH2 regulates the composition of basal-like breast cancer cell populations by promoting a M-bM-^@M-^\bi-lineageM-bM-^@M-^] differentiation state, in which cells co-express basal- and luminal-lineage markers. We show that human basal-like breast cancers contain a subpopulation of bi-lineage cells, and that EZH2-deficient cells give rise to tumors with a decreased proportion of such cells. Bi-lineage cells express genes that are active in normal luminal progenitors, and possess increased colony formation capacity, consistent with a primitive differentiation state. We found that GATA3, a driver of luminal differentiation, performs a function opposite to EZH2, acting to suppress bi-lineage identity and luminal progenitor gene expression. GATA3 levels increase upon EZH2 silencing, leading to the observed decrease in bi-lineage cell numbers. Our findings reveal a novel role for EZH2 in controlling basal-like breast cancer differentiation state and intra-tumoral cell composition. Total of four treatments (HCC70 cells stably expressing shEZH2, shEED, or EZH2 cDNA, and MDA-MB-468 cells stably expressing shEZH2) were done in duplicates, each with its own control.

2012-09-21 | E-GEOD-36939 | biostudies-arrayexpress

RNAseq of SKOV3(AA) and SKOV3(CC)

Project description:To study the effect of rs1192691 on ovarian cancer cells, we generated SKOV3(CC) from SKOV3(A/A) using CRISPR/Cas9 technology and performed RNA-seq.

2022-01-18 | GSE181884 | GEO

RNAseq of SKOV3(AA) and SKOV3(CC)

Project description:RNAseq of SKOV3(AA) and SKOV3(CC)

| PRJNA753808 | ENA